SCHEMBL5651272

SCHEMBL5651272

O=C(O)c1sc2c(ccc(=O)n2-c2ccccc2Cl)c1-c1ccccc1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK14 Q16539 4/20 0.39
NOTUM Q6P988 1/20 0.38
POLB P06746 1/20 0.37
MCL1 Q07820 2/20 0.35
MAPK1 P28482 1/20 0.35
ALDH1A1 P00352 4/20 0.35
RXFP1 Q9HBX9 1/20 0.35
MAP2 P11137 1/20 0.34
MAPK13 O15264 1/20 0.34
MAPK12 P53778 1/20 0.34
MAPK11 Q15759 1/20 0.34
HPGD P15428 2/20 0.33
CYP2C9 P11712 1/20 0.33
CYP2C19 P33261 1/20 0.33
LMNA P02545 1/20 0.33
GAA P10253 1/20 0.33
PPARG P37231 1/20 0.33
KMT2A Q03164 1/20 0.33
NCOA2 Q15596 1/20 0.33
NCOA1 Q15788 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5649242 0.87 MAPK14 (0.37) MAPK14NOTUMPOLBALDH1A1RXFP1
SCHEMBL5652104 0.85 ALDH1A1 (0.53) MAPK1ALDH1A1HPGDCYP2C19LMNA
SCHEMBL1266124 0.84 NOTUM (0.39) MAPK14NOTUMPOLBMCL1MAPK1
SCHEMBL5650705 0.83 KMT2A (0.43) MCL1MAPK1ALDH1A1HPGDCYP2C9
SCHEMBL5648156 0.81 FBP1 (0.42) ALDH1A1CYP2C9CYP2C19LMNAGAA
SCHEMBL2958928 0.74 CXCR2 (0.38) MAPK14NOTUMMAPK1ALDH1A1RXFP1
SCHEMBL5649654 0.73 ALDH1A1 (0.44) ALDH1A1MAP2HPGDCYP2C9KMT2A
SCHEMBL5652682 0.73 FBP1 (0.38) ALDH1A1HPGDCYP2C9CYP2C19LMNA
SCHEMBL2782770 0.72 GRM6 (0.40) MAPK14NOTUMALDH1A1RXFP1MAPK13
SCHEMBL5647917 0.72 ALOX5 (0.41) POLBALDH1A1HPGDCYP2C9CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7176215-B2 Bicyclic oxopyridine and oxopyrimidine derivatives CELLTECH R&D LIMITED (GB) 2007-02-13 US disclosed
US-20040254200-A1 Bicyclic oxopyridine and oxopyrimidine derivatives UCB PHARMA S.A. (BE) 2004-12-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040254200-A1 Bicyclic oxopyridine and oxopyrimidine derivatives MAPK1, ALK, NAT1 MAPK14 31/4885NOTUM 3645/4885POLB 199/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.